Table 1.
Demographic and clinical manifestations of 274 SLE patients
| Number of Patients | 274 | |
| Gender (%) | Female Male |
253 (92.3) 21 (7.7) |
| Age (years) (mean ± SD) at enrollment | 37.1 ± 13.1 | |
| Ethnicity (%) | Caucasian | 68 |
| Hispanic | 5 | |
| Asian | 8 | |
| Black | 16 | |
| Other | 3 | |
| Region (%) | Canada | 34 |
| US | 26 | |
| Mexico | 3 | |
| Europe | 32 | |
| Asia | 5 | |
| Single/Married/Other (%) | 39/43/18 | |
| Post secondary education (%) | 67 | |
| Disease duration (months) (mean ± SD) at enrollment | 5.9 ± 4.0 | |
| Number of ACR criteria (mean ± SD) | 4.8 ±1.0 | |
| Cumulative ACR manifestations (%) | ||
| Malar rash | 37 | |
| Discoid rash | 9 | |
| Photosensitivity | 43 | |
| Oral/nasopharyngeal ulcers | 42 | |
| Serositis | 26 | |
| Arthritis | 71 | |
| Renal disorder | 24 | |
| Neurological disorder | 9 | |
| Hematologic disorder | 53 | |
| Immunologic disorder | 70 | |
| Antinuclear antibody | 95 | |
| SLEDAI score (mean ± SD) at enrollment | 5.1 ± 5.4 | |
| SLICC/ACR score (mean ± SD) at enrollment | 0.31 ± 0.70 | |
| Medications (%) | ||
| Antimalarials | 69 | |
| Immunosuppressive drugs | 34 | |
| Oral corticosteroids | 62 | |
| Pulse IV corticosteroids | 4 | |
| Anticoagulants including warfarin, ASA | 25 | |
| Antidepressants | 19 | |
| Antiseizure drugs | 9 | |
| Other psychoactive drugs | 7 | |